Diaceutics PLC New Contract Wins (9186C)
24 Junio 2021 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 9186C
Diaceutics PLC
24 June 2021
24 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Multiple contracts for Inherited Retinal Disease (IRD) in APAC,
EU, and US markets
- Diaceutics is providing data analytics and implementation
solutions to enable seamless commercialisation of diagnostic
testing for leading global pharmaceutical companies ahead
of the launch of an innovative targeted therapy for IRD
- Projects cover comprehensive mapping of IRD testing landscapes,
including through the use of the Company's diagnostic
commercialisation platform DXRX, and test commercialisation
strategy implementation to ensure the right testing is
in place at launch, supporting increased uptake of the
therapy
- Contracts awarded cover key regional footprint extending
to Europe, the UK, APAC & the US
Diaceutics PLC, (AIM: DXRX), the diagnostics commercialisation
company for precision testing, announces it has secured four
projects with two leading pharmaceutical companies to solve
real-world testing hurdles for the rare disease group: Inherited
Retinal Disease (IRD). IRD has, until now, been a largely
untreatable disease group causing severe vision loss or even
blindness, affecting around two million people worldwide. The
contracts demonstrate the applicability of the DXRX diagnostic
commercialisation platform outside of the Company's core area of
oncology.
The services will be delivered over the course of six months in
2021 across Europe, the UK, APAC & the US. The projects are in
partnership with existing pharmaceutical customers of the Company
and represent an expansion of its commercial relationship into a
new therapy area, in line with the C ompany's 'land and expand'
strategy, and the increased engagement of the customers with the
DXRX platform. The contracts will deliver approximately GBP1.0
million revenue within 2021.
Peter Keeling, CEO and Founder of Diaceutics says, "Diaceutics
is excited to be involved with these ground-breaking therapies for
IRD, giving us an opportunity to bring our extensive knowledge of
personalized medicine in the oncology field to rare disease and to
help patients with IRD access the best treatments available. These
new project wins across a new disease area show the confidence that
leading pharma companies have in Diaceutics and our considerable
expansion opportunity. Through utilising the DXRX platform,
alongside our advisory services, the projects can be delivered
efficiently, at scale, across multiple geographies, bringing
together all the segments in the precision medicine diagnostics
market required to facilitate change and ensure patients get the
right treatment at the right time."
Diaceutics is the first to market with a unique diagnostic
commercialisation platform, DXRX, allowing stakeholders in the
precision medicine market to collaborate and shape the diagnostics
marketplace, in real time. Via the DXRX platform, the Group is
providing both data analysis services to pharmaceutical customers,
collected within the platform to highlight key opportunities and
hurdles that need to be considered for testing launch, and
subsequent implementation solutions, in which key testing
laboratories will be engaged to ensure seamless and high-quality
diagnostic testing is in place at the time of therapy launch.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Philip White, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUOSKRABUNUAR
(END) Dow Jones Newswires
June 24, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024